Published in J Obstet Gynaecol on October 01, 2006
Group A streptococcus: a continued threat. J Obstet Gynaecol (2006) 0.78
Are chlamydial infections the most prevalent venereal disease? JAMA (1975) 4.79
Titration and typing of serum antibodies in TRIC infections by immunofluorescence. J Immunol (1972) 3.17
Emergence of rifampin-resistance in Chlamydia trachomatis. Nature (1973) 3.06
Inhibition of TRIC agents by virus-induced interferon. Proc Soc Exp Biol Med (1966) 2.78
Latency in human infections with TRIC agents. J Immunol (1968) 2.73
Experimental inclusion conjunctivitis in man: measurements of infectivity and resistance. JAMA (1965) 1.97
Doxycycline treatment of chronic trachoma. JAMA (1973) 1.89
Human cell-mediated immune responses to chlamydial antigens. Infect Immun (1979) 1.76
Type-specific antibodies in human Chlamydia trachomatis infections of the eye. J Immunol (1974) 1.73
The challenge of patients' unmet palliative care needs in the final stages of chronic illness. Palliat Med (2007) 1.54
'I can't do any serious exercise': barriers to physical activity amongst people of Pakistani and Indian origin with Type 2 diabetes. Health Educ Res (2005) 1.46
Adenovirus type 8 keratoconjunctivitis in the United States. 3. Epidemiologic, clinical, and microbiologic features. Am J Ophthalmol (1970) 1.42
Training in clinical oncology: results of the Royal College of Radiologists' survey of new consultants. Clin Oncol (R Coll Radiol) (2012) 1.41
Small cell lung cancer treated in southeast Wales. Clin Oncol (R Coll Radiol) (2006) 1.40
Chlamydiae, cervicitis, and abnormal Papanicolaou smears. Obstet Gynecol (1979) 1.30
Characteristics of interferon induced in vitro and in vivo by a TRIC agent. Proc Soc Exp Biol Med (1966) 1.29
Antibodies to TRIC agents in tears and serum of naturally infected humans. J Infect Dis (1973) 1.22
Alcohol use patterns predict high-risk HIV behaviors among active injection drug users. J Subst Abuse Treat (2000) 1.21
Economic effects of community versus hospital-based faculty pneumonia care. J Gen Intern Med (1998) 1.20
Antibodies to TRIC agents in matched human tears and sera. J Immunol (1973) 1.19
Adenovirus type 8 infections in the United States. IV. Observations on the pathogenesis of lesions in severe eye disease. Arch Ophthalmol (1972) 1.19
Immunofluorescence in chronic TRIC infections of American Indians and Tunisians: influence of trauma on results of tests. Proc Soc Exp Biol Med (1971) 1.12
Immune responses to chlamydial antigens in humans. Med Microbiol Immunol (1982) 1.11
Effect of interferon on TRIC agents and induction of interferon by TRIC agents. Am J Ophthalmol (1967) 1.07
Experimental inclusion conjunctivitis in man. 3. Keratitis and other complications. Arch Ophthalmol (1967) 1.07
Controlled trials with trisulfapyrimidines in the treatment of chronic trachoma. J Infect Dis (1969) 1.05
Urinary albumin excretion in families with type 2 diabetes is heritable and genetically correlated to blood pressure. Kidney Int (2000) 1.04
Ovarian molar pregnancy. J Obstet Gynaecol (2008) 1.04
Experimental inclusion conjunctivitis in man. IV. The nature of the antibody response. J Immunol (1968) 1.04
An evaluation of the fluorescent antibody technic in the diagnosis of trachoma and inclusion conjunctivitis. Rev Int Trach (1968) 1.01
Cell-mediated and humoral immune responses to chlamydial antigens in guinea pigs infected ocularly with the agent of guinea pig inclusion conjunctivitis. Infect Immun (1981) 0.97
Diabetes service provision: a qualitative study of the experiences and views of Pakistani and Indian patients with Type 2 diabetes. Diabet Med (2006) 0.97
Diagnosis of Herpesvirus hominis infections in a general hospital laboratory. J Clin Microbiol (1975) 0.96
Tetracyclines in the treatment of chronic trachoma in American Indians. J Infect Dis (1971) 0.94
Controlled treatment trials of trachoma in American Indian children. Lancet (1967) 0.94
Experimental inclusion conjunctivitis in man. II. Partial resistance to reinfection. Am J Epidemiol (1966) 0.92
APOE polymorphisms and the development of diabetic nephropathy in type 1 diabetes: results of case-control and family-based studies. Diabetes (2000) 0.92
Herpetic whitlow as part of genital virus infection. J Infect Dis (1977) 0.92
Reduction in chlamydial infectivity by lysozyme. Proc Soc Exp Biol Med (1973) 0.92
Batch cultivation of Methylosinus trichosporium OB3b. I: Production of soluble methane monooxygenase. Biotechnol Bioeng (1991) 0.91
Thalidomide's long and winding road. BETA (1998) 0.91
Spontaneous ovarian abscess associated with an endometrioma. J Obstet Gynaecol (2007) 0.90
Chlamydial antigens stabilized with formalin for use in the micro-immunofluorescence test. J Clin Microbiol (1980) 0.90
Human follicular conjunctivitis caused by infection with a psittacosis agent. Proc Soc Exp Biol Med (1968) 0.89
Observed relationship between herpetic lesions and antigenic type of Herpesvirus hominis. Surv Ophthalmol (1976) 0.89
Herpesvirus infections in pregnancy: a comparison of neutralizing antibody titers in mothers and their infants. Am J Obstet Gynecol (1974) 0.88
Effect of seminal plasma on Chlamydia trachomatis strain LB-1 in cell culture. Infect Immun (1981) 0.87
Amino acid variants of the vitamin D-binding protein and risk of diabetes in white Americans of European origin. Eur J Endocrinol (1999) 0.86
Subclinical infections with TRIC agents. Am J Ophthalmol (1967) 0.86
Victims as victimizers: physical aggression by persons with a history of childhood abuse. Arch Intern Med (1999) 0.85
Cell-mediated immune responses to chlamydial antigens in guinea pigs injected with inactivated chlamydiae. Med Microbiol Immunol (1980) 0.82
Development and maintenance of a simple reflex circuit in small-patch mosaics of Drosophila: effects of altered neuronal function and developmental arrest. J Neurobiol (1993) 0.82
Quantitative assessment of the risk of lung cancer associated with occupational exposure to refractory ceramic fibers. Risk Anal (1999) 0.80
Infectivity for man of cell culture-adapted tric agents. Proc Soc Exp Biol Med (1967) 0.79
Chlamydial infection of neonates. J Infect Dis (1979) 0.79
Use of mental health services by HIV-infected women. J Womens Health (1997) 0.79
Long-term clinical, microbiological, and immunological observations of a volunteer repeatedly infected with Chlamydia trachomatis. J Clin Microbiol (1982) 0.79
Antibodies to two immunotypes of Chlamydia trachomatis in individuals with trachoma. Infect Immun (1976) 0.78
Use of antiretroviral therapies by HIV-infected persons receiving methadone maintenance. J Addict Dis (2000) 0.78
T-20: first of a new class of anti-HIV drugs. BETA (1999) 0.77
The menstrual cycle and viral load. BETA (1999) 0.77
Utilisation of beds on the general medical unit by 'non-acute medical' patients: a retrospective study of incidence and cost in two Tasmanian regional medical hospital units. Intern Med J (2014) 0.77
A case of heterotopic pregnancy following spontaneous conception. J Obstet Gynaecol (2014) 0.77
Nausea and vomiting. BETA (1997) 0.75
Analgesia for pelvic brachytherapy. Br J Anaesth (2002) 0.75
Open clinical trials for HIV/AIDS treatments. BETA (1997) 0.75
HAART appears to prevent mother-to-child HIV transmission. BETA (1999) 0.75
5-FU for maintenance therapy of cervical lesions. BETA (1999) 0.75
Ritonavir for preventing perinatal HIV transmission. BETA (1999) 0.75
San Francisco group demonstrates the ability of combination anti-HIV therapy to lower PHT. BETA (1998) 0.75
New microbicide enters clinical testing. BETA (1999) 0.75
Menses and duration of cycles. BETA (1999) 0.75
Herbs for HIV. BETA (1998) 0.75
Study to address effects of antiretroviral therapy on women. BETA (1999) 0.75
FTC: antiretroviral in development. BETA (1998) 0.75
Selected highlights from the National Conference on Women & HIV, Pasadena, CA, May 4-8, 1997. BETA (1997) 0.75
FddA: antiretroviral in development. BETA (1998) 0.75
Open clinical trials for HIV/AIDS treatments. BETA (1997) 0.75
Mycobacterium avium complex disease. BETA (1995) 0.75
Complementary and alternative medicine: exploring options and making decisions. BETA (1998) 0.75
Human papillomavirus infection and anal neoplasia. BETA (1997) 0.75
Calanolide A: a natural non-nucleoside reverse transcriptase inhibitor. BETA (1999) 0.75
Methisazone in progressive vaccinia. N Engl J Med (1967) 0.75
Epoietin alfa (EPO) for anemia. BETA (1998) 0.75
Syphilis. BETA (1999) 0.75
Double-blind treatment trials in chronic trachoma of American Indian children. Antimicrob Agents Chemother (Bethesda) (1967) 0.75
Conference news highlights. BETA (1995) 0.75
Pelvic inflammatory disease. BETA (1996) 0.75
HPV and neoplasia: notes from CROI. BETA (1999) 0.75
Intravaginal microbicidal gel to be tested. BETA (1999) 0.75
Sinusitis. BETA (1996) 0.75
Highlights from the Conference on Global Strategies on the Prevention of Mother-to-Child HIV Transmission. BETA (1998) 0.75
Promising findings from the PETRA study of perinatal transmission. BETA (1999) 0.75
HAART and HPV infection. BETA (1999) 0.75
Chinese medicine for HIV positive women. BETA (1997) 0.75
A new approach to initial antiretroviral therapy: protease-sparing combination regimens. BETA (1998) 0.75
HIV/AIDS in children: overview and guidelines for disease management. BETA (1996) 0.75
HIV prevalence remains stable in U.S. women through 1994. BETA (1999) 0.75
Vitamin A and HPV. BETA (1999) 0.75
Diabetes in women taking protease inhibitors. BETA (1999) 0.75